Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC

PHASE3TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

January 22, 2013

Study Completion Date

January 22, 2013

Conditions

HIV

Interventions

DRUG

Atazanavir

Capsule, oral, 300 mg, Once daily (QD), 96 weeks

DRUG

Ritonavir

Tablets, oral, 100 mg, QD, 96 Weeks

DRUG

Lamivudine

Tablet, oral, 300 mg, QD, 96 Weeks

DRUG

Tenofovir/Emtricitabine

Tablets, oral, 300/200 mg, QD, 48 Weeks